Cardio-Phoenix News & Updates
Evaluating NT-proBNP Thresholds and Referral Pathways in Heart Failure Diagnosis: A Comparative Analysis of NHS and EU Practices
NT-proBNP thresholds in heart failure diagnosis are essential for understanding how different healthcare systems identify and manage the disease. N-terminal pro B-type natriuretic peptide (NT-proBNP)…
The Decision to Order NT-proBNP: How ECG Findings and Clinical Factors Influence Testing
Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized as a common subtype of heart failure, particularly in older adults and women over the…
NT-proBNP Testing in Heart Failure with Preserved Ejection Fraction (HFpEF): Diagnostic Challenges and Clinical Implications
NT-proBNP in HFpEF diagnosis is increasingly recognized as a challenge, particularly among older women. Addressing these diagnostic challenges is critical because HFpEF now represents more…
The Impact of Obesity on NT-proBNP in Heart Failure: Focus on HFpEF and Early Diagnosis
Key takeaways (TL;DR): NT-proBNP in Heart Failure is central to diagnosis, but obesity complicates interpretation. Obesity has emerged as a significant health challenge, particularly as…
NT-proBNP and Diabetes: Risks of Misdiagnosis in Heart Failure
NT-proBNP and diabetes are closely linked, and this interplay can alter test interpretation in heart-failure diagnosis. N-terminal pro B-type natriuretic peptide (NT-proBNP) is a biomarker…
NT-proBNP in Heart Failure Diagnosis: Clinical Delay, Biomarker Limits, and the Need for Diagnostic Reinvention
Misconceptions, Misuse, and Missed Diagnoses in the Primary Care Pathway. Abstract – Misuse of NT-proBNP in Primary Care and Diagnostic Delays N-terminal pro B-type…
Categories
- Announcement (22)
- Events (9)
- Insights (10)
- Publications (10)
- Use Case (8)
